渐进性超核性:神经病理学,临床表现,诊断挑战,管理和新兴疗法
Frederick DeRosier1, Cody Hibbs1, Kaitlyn Alessi2
1Department of Foundational Sciences, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Clearwater, FL, United States of America.
Disease-a-month : DM
|June 22, 2024
概括
渐进性超核性麻 (PSP) 是一种导致神经退行症的病. 由于其破坏性和缺乏治疗方法,研究至关重要,正在开发针对tau的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 临床神经学 临床神经学
背景情况:
- 渐进性超核性 (PSP) 是一种神经退行性疾病,其特征是4R-tau蛋白聚合物.
- 病理性特征包括神经元损失,化和tau包容,影响脑干和基底腺.
- 独特的MRI发现,如蜂鸟和晨光标志,有助于诊断.
研究的目的:
- 提供关于PSP的当前知识的全面概述.
- 讨论PSP的发病,诊断和管理.
- 突出最近在PSP方面的进展和未来的研究方向.
主要方法:
- 对PSP现有文献的审查.
- 分析PSP的临床和病理特征.
- 讨论正在进行和未来的治疗策略.
主要成果:
- PSP具有临床异质性和各种表型,包括理查德森综合征 (PSP-RS).
- 常见的症状包括姿势不稳定,跌倒,垂直视力麻,布拉迪基尼西亚和认知障碍,通常与帕金森病重叠.
- 诊断挑战来自症状重叠与其他帕金森综合征.
结论:
- PSP是一种毁灭性的,无法治愈的疾病,在病理生理学,诊断和治疗方面存在重大知识差距.
- 目前正在研究针对tau修饰,微管相互作用或通过免疫疗法清除的新疗法.
- 持续的研究对于开发有效的治疗方法来减缓PSP进展至关重要.
相关概念视频
Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524
Parkinson's Disease: Treatment
255
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
255
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K


